At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
B LEO 35299 20 mg/g cream +5 moredrug
Likely dose
B LEO 35299 20 mg/g creamfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris
In Brief
A Phase 1 clinical trial evaluating B LEO 35299 20 mg/g cream, C LEO 35299 20 mg/g cream, and 4 other interventions for Psoriasis Vulgaris. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The purpose of the study is to evaluate the anti-psoriatic effect of LEO 35299 in different formulations, compared to Daivonex® ointment and Daivonex® ointment vehicle, using the psoriasis plaque test modified from the method developed by KJ Dumas and JR Scholtz.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis Vulgaris
CountriesFrance
Collaborators--
Timeline
Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2012
First PostedApr 2012
Primary CompletionJun 2012
TodayJul 2026
First PostedApr 19, 2012
Enrollment StartApr 1, 2012
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 14.2 years ago
Interventions
B LEO 35299 20 mg/g creamdrug
once daily application, 3 weeks
C LEO 35299 20 mg/g creamdrug
once daily application, 3 weeks
E LEO 35299 10 mg/g solutiondrug
once daily application, 3 weeks
F LEO 35299 10 mg/g solutiondrug
once daily application, 3 weeks
Daivonex® ointmentdrug
once daily application, 3 weeks
Daivonex® ointment vehicledrug
once daily application, 3 weeks